A typical patient on dialysis requires three sessions a week. Mondays, Wednesdays, Fridays, or Tuesdays, Thursdays, Saturdays, or some other combination of days. A typical insurance covers each of these episodes quite well. For example, all of these sessions are covered under Pradhan Mantri Jan Arogya Yojana (PMJAY). Under the code MG072D, dialysis is priced at 1,800 per session1, resulting in a reimbursement of 2.81 lakh a year. Anyone designing insurance would nod with satisfaction and move on. Three sessions, three reimbursements. That's how it should work.
However, reality tends to differ from theory by some distance in this case. PMJAY gives a family an insurance cover of 5 lakh per annum2. So a family with someone on dialysis sees 56% of their insurance cover go away before any of them gets sick.
Now if I were a rational, thinking man on dialysis with PMJAY as my only cover, how would I manage this? Answer: If I can, I'd reduce the number of sessions I undergo from 3 to 2 per week, which reduces my expenses from 56% of the household's entitlement to 37%. Still a lot, but it's two-thirds of where it used to be. My family now has a much better insurance cover than it would have if I were to follow current guidelines to the letter.
This is quite ironic if you read the PMJAY schedule properly. The scheme actually classifies acute and chronic haemodialysis differently (MG072C and MG072D respectively), yet prices them identically. That is quite an oversight by the team, because if you look really closely, episodic insurance for chronic haemodialysis has many blind spots.
Reimbursements and out of pocket expenditure
At first glance, the reimbursements look quite understandable. The measured cost of haemodialysis in a public-private partnership unit in Puducherry was found to be 1,856 per session3, out of which around 52% is fixed cost, 48% variable4 (the share is taken from another study: the two studies are 17 years apart, but adjusting numbers for inflation we see that the total expenditure noted in the earlier study inflates to what the later study reports).
However, as my experience in TB has taught me, the costs one sees on the face of it are rarely the actual costs borne by the patient. A study undertaken by AIIMS Raipur5 where around 78% of the participants were PMJAY recipients found median out of pocket expenditure to be around 17,058 rupees a month (IQR 11,923-26,673). This amounts to around 2.05 lakh a year, which is actually greater than the amount reimbursed to the centre in many cases.
The breakdown is also independently interesting. The median non-medical expenditure is around 4,300 rupees a month, and all of that is basically commute and food. So around a fourth of the expenditure goes to travelling to the dialysis centre and eating before your turn comes. The medical expenditure primarily covers vascular access, erythropoietin, blood transfusion and medication and is the rest of the out of pocket expenditure.
That's quite a severe oversight, so I sat down to dig into the PMJAY codes to understand what's covered and what's not. Lo and behold, all the medical expenditures listed above are covered!6 Unfortunately, providing all the services covered by PMJAY would cost the centre more than what the programme reimburses it for. Therefore, the centre does the only logical thing it can think of. It asks the patient to pay for it out of pocket. Is it fair? No. Is it rational? Yes! The centre has to be able to cover its costs if it wants to keep operating! The entitlement exists, it is merely unfunded.
And what about food and transport? Eagle eyed readers would counter my argument by pointing out that PMJAY does in fact allow for cost of transport and food to be reimbursed. Which is true, but only for hospitalisation, not for day procedures, which is what dialysis falls under.
This creates a perfect absurdity. A patient's out of pocket expenditure per month is actually greater than what the centre gets through reimbursement if the patient undergoes dialysis twice a week instead of the recommended thrice!
Rational choices?
The expenditure numbers I cite above are from a cohort where the overwhelming majority of patients were on twice-weekly dialysis, not thrice-weekly (which makes it worse, not better). When it comes to catastrophic health expenditure, there isn't a significant difference between the groups. 86% of the thrice-weekly group suffered from catastrophic health expenditure compared to 83% in the twice weekly group. That's a measurement artifact at best (and the sample size in the study was too small to measure this accurately), so even reducing the number of sessions being undertaken does not end up helping these households financially.
Then why do patients move from thrice weekly to twice weekly at all? Because that's the only lever they have to pull. And what does it lead to? One cannot reliably argue that it leads to them being under-dialysed because prevailing analysis does not actually say that twice-weekly is in any way inferior to thrice-weekly. Start off at twice-weekly, keep measuring, and then escalate to thrice weekly as residual kidney function declines is a perfectly legitimate way of taking care of a patient.
The actual problem is that in a good, rational dialysis programme, that measurement would happen and the patient would be moved from twice-weekly to thrice-weekly. Over here, we see patients starting from a twice-weekly regimen (or migrating to it) not because the doctor suggested it, but because their insurance regimen forces them into this situation.
This is not a small problem. It has been reported many times that mortality rate differences are not easily measurable (or maybe do not exist) between groups on incremental dialysis and regular dialysis cadences7. However, there is an asterisk to that fact. It is true for patients whose baseline renal urea clearance is above 3.0 mL/min/1.73m². Below that, there's a 61% higher hazard of death among those on incremental dialysis as compared to regular dialysis.8 This measurement also has to be made monthly, because even amongst patients who clear that bar, up to 30% lost a quarter of their residual kidney function within 3 months, so for a sizable number the value that makes twice-weekly dialysis safe is stale before the year is out.9
It's the money, stupid!
Let's go back to the patient making a choice. Multiple studies have found that patients start out with regular dialysis, often in private facilities, run out of money, and move to public facilities with fewer sessions a week10. Financial pressure should not be a reason people move to a different regimen, but it's an imperfect world, and there's no good way of preventing that. In fact, nephrologists themselves recognise that there's a body of literature built around people who move between thrice a week and twice a week dialysis due to non-medical confounding reasons, therefore all such conclusions should be taken with a pinch of salt.11
To be sure that it isn't something specific to PMJAY, I turned to look at another country which has a similar programme and sits right next door. I am, of course, talking about Pakistan. Sehat Sahulat Programme is their equivalent of PMJAY12 with a similar format for paying off dialysis costs. They reimburse centres assuming episodic treatments. A study from Pakistan reveals the same problem afflicting their dialysis patients as well. In fact, 28.6% of the households in that study had expenses which exceeded their entire monthly household income.13
Unfortunately, there are more monetary nuances to this problem than the ones we've talked about. PMJAY covers dialysis episodes, but surprisingly, not the prep required for it. Performing dialysis means getting access to blood. Given the rate at which blood flows during dialysis, you need to tap into a large vein or artery. The recommended way to do that is through an arteriovenous fistula. A surgeon joins an artery to a vein in the arm, and it takes 6 - 12 weeks to dilate until it can take dialysis pressure. This procedure is technically an elective surgery, because you do not need it at that time. The recommendation is to do this to a patient who has not yet started dialysis in anticipation that the patient will start soon.
Unfortunately, PMJAY does not cover fistula creation in a pre-dialysis patient. To be very clear, the norm around the world is to start out on temporary catheters (which are associated with higher mortality rates than properly created fistulas)14 until a fistula is created, but the reasons cited around the world have more to do with shortage of available surgeons15 and not because of unwillingness to pay. PMJAY pays for this specific surgery after a patient is already on dialysis, which is good, it's not out-of-scope, at least, but catheter-based infections are a significant source of hospitalisations amongst this group, which again, taps into the PMJAY allowance each family gets.
And finally, there is a way to get out of this cycle which the PMJAY pays for. Kidney transplant. Let's leave aside the problems with legally and ethically getting a kidney which actually works for you. Once you get the transplant done, you need immunosuppression for life. PMJAY covers this. Unfortunately, it only covers this for a single year.16 Once the year runs out, you're on your own and the yearly burden would be around a lakh. An episodic insurance does have the machinery to cover non-episodic treatments, but it limits it to a certain time period, following which a person whose transplant is rejected by his body due to not getting the proper immunosuppressants goes back to dialysis which costs the insurance more than what giving the full regimen of immunosuppressants would.
Public Sector solutions
So is the situation hopeless? No. Nationally the answer which is typically pointed towards is the Pradhan Mantri National Dialysis Programme (PMNDP)17, which makes the dialysis session free at the point of care, but only for BPL patients. Just like the PMJAY, it only covers the session, and nothing else. All dialysis-related costs remain what they were, and the study done at Raipur actually shows patients moving from private care to public care (from non-PMNDP care to PMNDP care) as the costs of dialysis begin to bankrupt them. This is a hugely consequential programme which benefits a lot of people, but just like PMJAY, it does not go nearly far enough.
A few states have noticed this gap and gone beyond. Chhattisgarh has a state level cover which goes beyond the PMJAY up to 20 lakhs a year, reserved for conditions the PMJAY package list does not cover.18 It covers continuous ambulatory peritoneal dialysis (CAPD), which requires very little travel and is not episodic at all (hence the name). The procedure itself costs around 3.42 lakh annually, which is greater than the 3.17 lakh measured for regular haemodialysis.19 To compare, PMJAY only covers catheter review (for up to 1,000 rupees). Andhra Pradesh offers a direct benefit transfer to "people affected with Chronic Kidney Disease who are undergoing Dialysis, both Government and network hospitals" to the tune of 10,000 rupees a month20. It doesn't cover every identified cost, but it goes a long way towards making the burden easier to shoulder. Maharashtra attacks this problem directly, naming AV fistula creation and immunosuppression support for up to three years as part of their state level insurance programme.21
Out of all these approaches, Andhra Pradesh's answer seems to be the one which has the greatest chance of working. The state has independently arrived at the answer which the TB programme did with Nikshay Poshan Yojana22 - the problem isn't merely getting drugs to the TB/CKD patient, the problem is everything around it. All the medication in the world doesn't benefit you unless your body can actually grow, build, and fight back. Your system needs to support you else the intervention itself can just fail and you're back to square one.
In fact, the railways ministry actually grant a 75% concession on mail and express fares to kidney patients travelling for dialysis along with an escort. They also exempt kidney patients from the minimum required distance of 300 km which applies to most concessions because someone in the railway ministry has worked out that people going for dialysis make these short journeys over and over again.23. That a ministry dealing with transport has actually been able to accurately model travel patterns of kidney patients is both darkly funny and somehow simultaneously very sad.
Private players
And what does all of this mean for private players? Indian healthcare sees private players perform the lion's share of all dialysis in the country. And they operate in a setting where their profit motive and the correct clinical guidelines both point in the same direction: more sessions per patient.
The problem is that this is an industry where patients are structurally unable to pay. Revenue is a function of sessions. Whether patients pay out of pocket or via PMJAY, revenues depend on the number of sessions a provider is able to run. So the answer is actually straightforward. Increase the number of sessions.
Fortunately, the marginal cost of a third session in existing shifts is actually lower than the total cost a provider may charge, because the consumables are technically the only things which get used up per new session at this point. This is scant consolation to someone who uses PMJAY, because PMJAY deducts the same amount per session regardless of the actual operating costs of the provider, but it does have the potential for the provider to incentivise a patient who pays out of pocket using differential pricing.
The flip side, of course, is that if per-session charges could be dropped to get more patients in, maybe they would have been. So the direction of movement must be towards reducing catastrophic expenditure by the patient so they're able to afford more sessions. Proactive AV fistula creation may be one way in which this can be done. Another way to look at it is to think about the lifetime value created by a patient. Approximately 150 sessions a year for a lifetime is a very long association between provider and patient. If the provider starts with a twice-weekly routine, checking kidney function periodically, and switches to thrice-weekly when tests indicate it is time to do so, it might end up benefiting both the patient and the provider.
Conclusion
The US has a voluntary programme underway called Kidney Care Choices24 since 2022 across CKD 4, CKD 5 and ESRD: capitation plus shared savings, with the total cost of a patient's care as the measure, and until this year, a $15,000 bonus for a transplant. It's under evaluation, but it is explicitly trying to prove that provider payment reform can be made to work out for continuous kidney care. The first evaluations have found more home dialysis, more optimal starts to dialysis and more preemptive and living donor transplants, alongside a net loss to Medicare of around $304 million in 2023.
But whether it works or not, the structure of the programme is worth understanding. The programme tries to price things that an episodic insurance programme cannot see - admissions that didn't happen and the patients who leave dialysis altogether. Both are invisible to an insurance which only looks at episodes.
The 5 lakh PMJAY family floater is designed to stop a single hospital admission from ruining a family. It definitely succeeds in that. Dialysis, however, is not an admission. It is a chronic condition. It is a standing order against a household's income for the rest of someone's life, and pricing it per session is how the vast majority of dialysis households end up catastrophically poor even as official figures record them as covered.
National Health Benefit Package (HBP) 2022, National Health Authority. MG072C Acute Haemodialysis and MG072D Chronic Haemodialysis are both priced at Rs 1,500 / 1,800 / 1,800 by hospital tier. MG072A Haemodialysis is a separate add-on procedure at a flat Rs 1,500, and MG072B Peritoneal Dialysis covers catheter review at Rs 500 / 700 / 875 plus Rs 1,000 for consumables.
Ayushman Bharat Pradhan Mantri Jan Arogya Yojana provides Rs 5 lakh per family per year for secondary and tertiary care hospitalisation.
Sahithya V, Sivanantham P, Anandraj J, Parameswaran S, Sekhar Kar S. Economic cost of hemodialysis and peritoneal dialysis under public-private partnership in a public tertiary care centre of Puducherry, India. Expert Review of Pharmacoeconomics and Outcomes Research 2024. PMID 39648305, DOI 10.1080/14737167.2024.2439515. Bottom-up costing at JIPMER Puducherry, cost year October 2021 to 2022, capital annualised and discounted at 3%. Unit cost per haemodialysis session Rs 1,856 (USD 22) and per CAPD exchange Rs 323 (USD 4). Annual cost per beneficiary Rs 316,618 (USD 3,820) for haemodialysis and Rs 341,979 (USD 4,126) for CAPD.
Khanna U. The Economics of Dialysis in India. Indian Journal of Nephrology 2009;19(1):1-4. DOI 10.4103/0971-4065.50671, PMID 20352002, PMC2845186. Per session running cost in 2009 rupees: consumables Rs 350, electricity Rs 50, water/telephone/insurance Rs 10, annual maintenance Rs 20, repairs and wear and tear Rs 20, depreciation Rs 100, honorarium to nephrologist Rs 100 to 200, staff salary Rs 100 to 200, total Rs 750 to 950. The fixed and variable split is taken from this structure, not from the Puducherry figure. On the inflation adjustment: India CPI (all items, 2015 = 100) stood at 60.09 in 2009 and about 138.4 over the Puducherry cost year of October 2021 to 2022, a multiplier of 2.30. Khanna's Rs 750 to 950 therefore comes forward to roughly Rs 1,730 to 2,190, a range which contains the measured Rs 1,856. CPI is a general index rather than a healthcare deflator, and the two settings differ, so this establishes the same order of magnitude and no more.
Ramasamy S, Gahlawat S, Galhotra A, Rathore V. Financial strain beyond coverage: assessing out-of-pocket costs for dialysis care in chronic kidney disease at a tertiary care centre in Central India. Cost Effectiveness and Resource Allocation 2026;24:75. PMID 42050537, DOI 10.1186/s12962-026-00753-w. n = 99, complete enumeration, 78.7% on PM-JAY, 78.8% on twice weekly dialysis. Catastrophic health expenditure above 40% of household income in 83 of 99 (84%), 100% of the uninsured and 80% of the insured; 65 of 78 (83%) on twice weekly and 18 of 21 (86%) on thrice weekly.
National Health Benefit Package 2.2 manual, National Health Authority. Package rates are stated to include medicines and drugs, blood transfusion, consultant fees, basic pathology and radiology, and medicines for up to 15 days after discharge. Food to patient appears in the hospitalisation inclusion list and is absent from the daycare list. Transport appears in neither.
Hazara AM et al. Incremental Hemodialysis Practices and Impact on Survival. Kidney Medicine 2026, PMID 41767695: 14 studies, 91,928 participants, mortality HR 0.97 (95% CI 0.76 to 1.19). Caton E et al. NDT 2022, PMID 36130107: HR 0.99 (0.80 to 1.24). Takkavatakarn K et al. Clinical Kidney Journal 2024, PMID 38186889: 36 studies, 138,939 participants, mortality OR 0.87 (0.72 to 1.04). Garofalo C et al. Journal of Nephrology 2019, PMID 30604150.
Obi Y et al. Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients. AJKD 2016, PMID 26867814. Incremental regimens carried HR 1.61 (95% CI 1.07 to 2.44) where baseline renal urea clearance was at or below 3.0 mL/min/1.73m2, and HR 0.99 (0.76 to 1.28) above it. The threshold is not specific to this study. The 2015 KDOQI Hemodialysis Adequacy guideline update already permits a reduced weekly dialysis dose where residual kidney urea clearance is measured and adequate, reported in the nephrology literature as above 3 mL/min/1.73m2 (Rhee et al., PMID 28090764; PMID 34327218) and elsewhere as 2 mL/min/1.73m2 or more (PMID 26924065). The guideline text itself has not been consulted here, so the figure is given as the range those sources report.
Accelerated Loss of Residual Kidney Function in Incremental Hemodialysis. PMID 40062122. A retrospective series of 37 incident patients started on twice-weekly incremental haemodialysis between March 2017 and May 2022, admitted on a residual urea clearance of at least 3 mL/min/1.73m2, urine output of at least 500 mL a day, and the ability to comply with monthly interdialytic urine collection. Of the 30 with complete data, 9 (30%) met the definition of accelerated loss, a fall of 25% or more in residual urea clearance from baseline within three months. The series is small and single-centre.
Elias MA, Van Damme W, Wouters E. Accessibility and quality of haemodialysis services in an urban setting in South India: a qualitative multiperspective study. BMJ Open 2022, PMID 35131824, DOI 10.1136/bmjopen-2021-052525. Patients started in private facilities, later shifted to government and NGO run centres, and reduced the number of weekly sessions due to financial constraints.
Casino FG, Murea M, Floege J, Zoccali C. Incremental dialysis: two complementary views. Clinical Kidney Journal 2024, PMID 38404364. Murea notes that most of the evidence derives from retrospective and observational studies which can be influenced by socioeconomic constraints, and that nephrologists hesitate partly because of financial disincentives.
Sehat Sahulat Programme, Government of Pakistan, administered through State Life Insurance Corporation. Cashless inpatient treatment at empanelled hospitals, split into a secondary care limit and a larger priority treatment limit covering dialysis, cardiac care, cancer and transplant.
Economic Burden and Clinical Epidemiology of Dialysis: A Cross-Sectional Analysis of Chronic Kidney Disease Patients. Cureus 2026, PMID 41164067. n = 42 at a secondary care hospital in Pakistan; 95.2% on twice weekly haemodialysis; all patients incurred recurring out-of-pocket costs despite sessions being fully covered; 28.6% of households exceeded 100% of monthly household income once ancillary costs were counted.
Lorenzo V et al. Predialysis nephrologic care and a functioning arteriovenous fistula at entry are associated with better survival in incident hemodialysis patients. AJKD 2004, PMID 15168379: catheter initiation HR 1.75, unplanned presentation HR 1.73 (95% CI 1.23 to 2.44). US registry data, Hemodialysis access at initiation in the United States 2005 to 2007, PMID 19758304: 63.2% started on a catheter alone, adjusted mortality hazard 1.49 (1.44 to 1.55) against fistula.
Haemodialysis vascular access: current practices amongst Indian nephrologists. Journal of Vascular Access, PMID 29192721: 59% of responding nephrologists reported that more than three quarters of their patients start dialysis with an uncuffed catheter. Ramachandran R et al. Interventional nephrology and vascular access practice: a perspective from South and Southeast Asia. PMID 33934667: 43% and 70% unplanned initiation across country groups. Global variability of vascular and peritoneal access for chronic dialysis, PMID 38018697: in 31 countries more than 75% of patients initiated haemodialysis with a temporary catheter, with shortages of surgeons named as a cause.
HBP 2022, package OT001 Renal Transplant. OT001D Post-Transplant Medication Month 1 to 3, OT001E Month 3 to 6 and OT001F Month 6 to 12, each labelled an Additional Procedure, together covering roughly Rs 1.4 to 1.5 lakh. Published state copies differ on the individual tier rates. No code covers immunosuppression beyond month 12.
Pradhan Mantri National Dialysis Programme, launched 7 April 2016 under the National Health Mission in PPP mode. PIB release 2297506, 11 August 2026: as on 30 June 2026, 1,856 haemodialysis centres with 13,535 machines across 751 districts including 44 linked districts, in all 36 States and UTs. The programme has haemodialysis and peritoneal dialysis components and supports free services for patients below the poverty line.
Mukhyamantri Vishesh Swasthya Sahayata Yojana, Government of Chhattisgarh, which covers conditions outside the AB PM-JAY package list. Continuous ambulatory peritoneal dialysis was included in May 2022; see Increased Uptake of Peritoneal Dialysis after Inclusion of Peritoneal Dialysis in MVSSY, Indian Journal of Nephrology, PMC11044668.
Sahithya V, Sivanantham P, Anandraj J, Parameswaran S, Sekhar Kar S. Economic cost of hemodialysis and peritoneal dialysis under public-private partnership in a public tertiary care centre of Puducherry, India. Expert Review of Pharmacoeconomics and Outcomes Research 2024. PMID 39648305, DOI 10.1080/14737167.2024.2439515. Bottom-up costing at JIPMER Puducherry, cost year October 2021 to 2022, capital annualised and discounted at 3%. Unit cost per haemodialysis session Rs 1,856 (USD 22) and per CAPD exchange Rs 323 (USD 4). Annual cost per beneficiary Rs 316,618 (USD 3,820) for haemodialysis and Rs 341,979 (USD 4,126) for CAPD.
NTR Bharosa Pension Scheme, Government of Andhra Pradesh, G.O.Ms.No.43 dated 13 June 2024, payable from July 2024. Rs 10,000 per month for people with chronic kidney disease undergoing dialysis at government and network hospitals, and the same for kidney, liver and heart transplant recipients.
Mahatma Jyotiba Phule Jan Arogya Yojana, Government of Maharashtra, which supports renal transplantation surgery, AV fistula and donor nephrectomy, post transplant immunosuppression for up to three years including specified investigations, and dialysis.
Ni-kshay Poshan Yojana, Central TB Division, Ministry of Health and Family Welfare. Launched in 2018, a direct benefit transfer for nutritional support to every notified tuberculosis patient for the full duration of anti-TB treatment. The monthly amount was raised from Rs 500 to Rs 1,000 in October 2024 (PIB release 2062928, 7 October 2024), giving Rs 3,000 to Rs 6,000 per patient over a course of treatment. Rs 3,202 crore had been disbursed to 1.13 crore beneficiaries as at that date.
Indian Railways concession list, category II (Patients), item 8: "Kidney patients travelling alone or with an escort for kidney transplant Operation/ Dialysis", at 75% in second class, sleeper, first class, 3AC and AC chair car and 50% in 1AC and 2AC, with one escort eligible for the same concession. Concessions do not extend to supplementary charges such as the superfast surcharge or reservation fee. The general rules impose a minimum journey of 300 km, from which kidney patients are expressly exempted along with students, persons with blindness, TB and cancer patients, non-infectious leprosy patients, thalassemia major, heart and haemophilia patients and their escorts. Concession list as compiled at https://www.staffnews.in/2025/06/concession-on-indian-railways-in-rail-fares.html, current as at June 2025.
Kidney Care Choices model, Centers for Medicare and Medicaid Services Innovation Center. Voluntary, launched 2022 and scheduled to run through 2027, covering Medicare beneficiaries with CKD stage 4, CKD stage 5 and ESRD. Nephrology practices receive adjusted capitation payments for managing aligned beneficiaries, adjusted on health outcomes, utilisation and quality measures; the Comprehensive Kidney Care Contracting options carry 50% or 100% risk on the total cost of care for Medicare Parts A and B. A Kidney Transplant Bonus of 15,000 dollars per beneficiary, paid in instalments over three years and conditional on the transplant remaining successful, applied until performance year 2026. CMS announced in May 2025 that transplants performed from PY 2026 onwards would no longer receive it, as part of a set of changes to improve the model's sustainability. Published evaluations found higher rates of home dialysis, home dialysis training and optimal dialysis starts, no significant change in transplant rates in the first year, increased preemptive and living donor transplants by the second, and a net loss to Medicare of approximately 304 million dollars in PY2023.

